alzamend neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of alzheimer’s disease, bipolar disorder, major depressive disorder (“mdd”) and post-traumatic stress disorder (“ptsd”). our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ million americans suffering from these debilitating diseases. our current pipeline consists of two novel therapeutic drug candidates, al001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and alzn002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat alzheimer’s.
Company profile
Ticker
ALZN
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
811822909
ALZN stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
29 Mar 24
10-Q
2024 Q3
Quarterly report
25 Mar 24
DEF 14A
Definitive proxy
25 Mar 24
8-K
Entry into a Material Definitive Agreement
22 Mar 24
NT 10-Q
Notice of late quarterly filing
18 Mar 24
PRE 14A
Preliminary proxy
13 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
7 Mar 24
8-K
Entry into a Material Definitive Agreement
2 Feb 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
10-Q
2024 Q2
Quarterly report
15 Dec 23
Latest ownership filings
4
MILTON C AULT III
23 Apr 24
4
MILTON C AULT III
3 Apr 24
4
MILTON C AULT III
1 Apr 24
4
MILTON C AULT III
28 Mar 24
SC 13D/A
AULT MILTON C III
2 Feb 24
4
MILTON C AULT III
2 Feb 24
SC 13D/A
AULT MILTON C III
25 Jan 24
4
MILTON C AULT III
25 Jan 24
4
MILTON C AULT III
9 Jan 24
4
MILTON C AULT III
27 Dec 23
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Apr 23 | Apr 22 | Apr 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 200.08 k | 200.08 k | 200.08 k | 200.08 k | 200.08 k | 200.08 k |
Cash burn (monthly) | 498.45 k | 748.56 k | 967.24 k | 1.26 mm | 504.47 k | 737.81 k |
Cash used (since last report) | 2.95 mm | 4.44 mm | 5.73 mm | 7.49 mm | 2.99 mm | 4.37 mm |
Cash remaining | -2.75 mm | -4.24 mm | -5.53 mm | -7.29 mm | -2.79 mm | -4.17 mm |
Runway (months of cash) | -5.5 | -5.7 | -5.7 | -5.8 | -5.5 | -5.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 6 |
Closed positions | 5 |
Increased positions | 5 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 1.49 bn |
Total shares | 21.27 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Milton C Ault Iii | 15.00 mm | $15.90 mm |
TFC Truist Financial | 2.31 mm | $548.63 mm |
Vanguard | 2.04 mm | $482.36 mm |
Geode Capital Management | 636.01 k | $150.78 mm |
BLK Blackrock | 596.13 k | $141.28 mm |
RFG Advisory | 250.00 k | $59.25 mm |
NTRS Northern Trust | 103.78 k | $24.60 mm |
Charles Schwab Investment Management | 53.08 k | $12.58 mm |
Tower Research Capital | 48.61 k | $11.52 mm |
BK Bank Of New York Mellon | 40.37 k | $9.57 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Apr 24 | Milton C Ault Iii | Common Stock | Buy | Acquire P | Yes | No | 0.6882 | 1,000 | 688.20 | 771,699 |
1 Apr 24 | Milton C Ault Iii | Common Stock | Buy | Acquire P | Yes | No | 0.9109 | 334 | 304.24 | 770,699 |
26 Mar 24 | Milton C Ault Iii | Warrants Common Stock | Buy | Acquire P | Yes | No | 1.2 | 780,000 | 936.00 k | 2,000,000 |
26 Mar 24 | Milton C Ault Iii | Series B Convertible Preferred Stock Common Stock | Buy | Acquire P | Yes | No | 1000 | 780 | 780.00 k | 2,000 |
23 Jan 24 | Milton C Ault Iii | Common Stock | Other | Dispose J | Yes | No | 0 | 661,168 | 0.00 | 5,498 |
23 Jan 24 | Milton C Ault Iii | Warrants Common Stock | Other | Dispose J | Yes | No | 45 | 666,666 | 30.00 mm | 0 |
5 Jan 24 | Milton C Ault Iii | Common Stock | Buy | Acquire P | Yes | No | 1.0635 | 2,000 | 2.13 k | 770,365 |
News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
16 Apr 24
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
4 Apr 24
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
2 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
27 Mar 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
13 Feb 24